BioCentury | Sep 5, 2019
Financial News

Sept. 5 Financial Quick Takes: Zealand raises cash as it readies NDA; plus Bellus, Aerie, LNC, Veralox and Sigrid

Ahead of NDA submission, Zealand raising cash Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) is raising DKK559.6 million ($82.4 million) via a private placement and directed share issue to existing investor Van Herk Investments. Zealand will sell...
BioCentury | Apr 6, 2018
Clinical News

MediciNova's tipelukast meets in Phase IIa for liver disease

...Tipelukast is a leukotriene receptor antagonist and inhibitor of phosphodiesterase-3 (PDE-3), PDE-4 and 5-lipoxygenase (ALOX5; 5-LO...
...PDE-3); PDE-4; 5-lipoxygenase (ALOX5; 5-LO) Description: Leukotriene receptor antagonist and inhibitor of PDE-3, PDE-4 and ALOX5...
...in the liver Status: Phase IIa data Milestone: NA Jennie Walters tipelukast (MN-001, kca-757) Kyorin Pharmaceutical Co. Ltd. MediciNova Inc. 5-lipoxygenase (ALOX5) (5-LO) Phosphodiesterase-3...
BioCentury | Apr 2, 2018
Clinical News

Early stop in liver disease trial boosts MediciNova

...Tipelukast is a leukotriene receptor antagonist and inhibitor of phosphodiesterase-3 (PDE-3), PDE-4 and 5-lipoxygenase (ALOX5; 5-LO...
...treat methamphetamine dependence (see BioCentury Extra, March 29) . Jennie Walters tipelukast (MN-001, kca-757) Kyorin Pharmaceutical Co. Ltd. MediciNova Inc. 5-lipoxygenase (ALOX5) (5-LO) Phosphodiesterase-3...
BioCentury | Feb 9, 2018
Product R&D

R is for readout

...hyperphosphatemia Phase III AZD7986 (INS1007) dipeptidyl peptidase-1 (DPP-1; CTSC)-inhibitor Non-cystic fibrosis bronchiectasis Phase II AZD5718 5-lipoxygenase...
BioCentury | Jan 2, 2018
Distillery Therapeutics

Hepatic

INDICATION: Hepatic Patient sample, mouse, pig and macaque studies suggest inhibiting ALOX12 could help treat ischemia/reperfusion-induced liver injury. In liver samples from hepatocellular carcinoma (HCC) or hepatic cyst patients undergoing surgical liver resection, levels of...
BioCentury | Feb 18, 2016
Distillery Therapeutics

Therapeutics: 5-lipoxygenase (ALOX5; 5-LO)

...Cancer INDICATION: Breast cancer Mouse studies suggest inhibiting ALOX5 could help treat metastatic breast cancer. In...
...help treat metastatic breast cancer. In a mouse model of spontaneous breast cancer, the generic ALOX5...
...S.p.A. and Vansen Pharma Inc. market the ALOX5 inhibitor zileuton for asthma. TARGET/MARKER/PATHWAY: 5-lipoxygenase (ALOX5; 5-LO...
BioCentury | Jan 18, 2016
Clinical News

Tipelukast: Phase IIa started

...receptor Description: Leukotriene receptor antagonist and an inhibitor of phosphodiesterase-4 (PDE-4), 5-lipoxygenase ( ALOX5 ; 5-LO...
BioCentury | Sep 21, 2015
Clinical News

Tipelukast regulatory update

...a leukotriene receptor antagonist and an inhibitor of phosphodiesterase-4 (PDE-4) , 5-lipoxygenase ( ALOX5 ; 5-LO...
BioCentury | Aug 27, 2015
Distillery Therapeutics

Therapeutics: Cyclooxygenase-2 (COX-2); 5-lipoxygenase (ALOX5; 5-LO)

...Inflammation INDICATION: Inflammation; pain In vitro and mouse studies suggest an inhibitor of COX-2 and ALOX5...
...pain and inflammation. Chemical synthesis of barbituric acid analogs followed by testing in COX-2 and ALOX5...
...the long-term in vivo toxicity of the lead compound. TARGET/MARKER/PATHWAY: Cyclooxygenase-2 (COX-2) ; 5-lipoxygenase (ALOX5; 5-LO...
BioCentury | Jul 27, 2015
Clinical News

NPH29: Clinical trial data

...stem cell factor (SCF) receptor tyrosine kinase (c-Kit; KIT; CD117) and 5-lipoxygenase ( ALOX5 ; 5-LO...
Items per page:
1 - 10 of 184